For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

Obesity Drug Access in the UK: NHS Rollout and Private Market Dynamics

Sep 29, 2026
Obesity Drug Access in the UK: NHS Rollout and Private Market Dynamics

In the UK, access to obesity drugs is currently divided into two distinct pathways: a publicly funded rollout by the NHS and a rapidly expanding private market. The NHS's approach to the rollout of tirzepatide, marketed as Mounjaro, is phased over a long period of up to 12 years. In contrast, the private market has seen a much quicker adoption of these medications. A survey conducted by University College London (UCL) estimates that approximately 1.6 million British adults utilized these medications for weight loss within a single year, with two new oral GLP-1 medications available exclusively through private prescriptions.

As of September 2026, the NHS has established specific eligibility criteria for accessing tirzepatide. According to the National Institute for Health and Care Excellence (NICE), individuals must have an initial body mass index (BMI) of at least 35 kg/m² and at least one weight-related comorbidity. NHS England estimates that this population comprises around 3.4 million individuals. NICE's technology appraisal TA1026, published on December 23, 2024, confirmed the funding variation requested by NHS England, allowing the full eligible population to gain access to the medication over a maximum of 12 years. The initial target for the first three years is approximately 220,000 patients.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

From March 24, 2025, integrated care boards (ICBs) were mandated to fund treatment through specialist weight management services for those meeting the NICE criteria. Primary care services began funding treatment on June 23, 2025, but only for prioritized cohorts specified by NHS England. The first cohort, Cohort I, requires a BMI of 40 or higher along with at least four out of five qualifying conditions, which include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. Cohort II lowers the BMI requirement to between 35 and 39.9, maintaining the same four-condition test, while Cohort III includes individuals with a BMI of 40 or more and three qualifying conditions, with adjusted thresholds for certain ethnic backgrounds.

Support for diet and behavior change is mandatory, with a minimum duration of nine months for those receiving treatment through primary care. Clinicians are expected to reassess treatment if a patient does not lose at least 5 percent of their initial weight after six months, applying this assessment at the highest tolerated dose. Unlike other NICE-recommended weight management medications, tirzepatide does not have a specified stopping rule.

However, the rollout has faced challenges. An investigation by The BMJ in September 2025 revealed that only 18 out of 42 ICBs had begun prescribing in accordance with the rollout plan, with just nine confirming funding for at least 70 percent of eligible patients. Jonathan Hazlehurst from the University of Birmingham noted that the initial funding only covers about 10 percent of the three-year target, while Ellen Welch, co-chair of Doctors’ Association UK, criticized the rollout as being unfit for purpose.

The most comprehensive data on NHS obesity drug access comes from the National Evaluation of Weight Medication Access (NEWA), funded by the National Institute for Health and Care Research. The first paper from this evaluation, posted on medRxiv on July 27, 2026, has not yet undergone peer review. It indicates that eight of the 39 ICBs with access criteria have implemented additional local prioritization due to funding limitations. Notably, there was no significant increase in tirzepatide prescribing for obesity between June 2025 and January 2026, beyond existing diabetes trends.

Measurement issues complicate the situation, as NHS England Digital reports that tirzepatide is marketed under a single brand name for both diabetes and obesity, making it difficult to separate the two uses in prescribing data. Concerns have also been raised regarding the potential for uneven GP participation in the Quality and Outcomes Framework (QOF), which could exacerbate health inequalities.

Demand for obesity medications is evident, with a UCL study published in BMC Medicine in January 2026 indicating that 2.9 percent of adults, approximately 1.6 million people, had used a GLP-1 medication for weight loss. This figure exceeds NHS England's initial goal of prescribing these drugs to 220,000 individuals over three years. Price remains a significant barrier for those seeking private access to obesity drugs, with Eli Lilly increasing the list price of Mounjaro in September 2025. Monthly prices now range from £133 to £330, depending on the dosage, while private providers have priced the new oral options, such as Wegovy and Foundayo, lower than Mounjaro.

The General Pharmaceutical Council (GPhC) has raised concerns about the standards of online supply for obesity medications, highlighting weaknesses in risk assessment and clinical governance. NHS England requires that commissioned online pathways adhere to GPhC guidelines, particularly for high-risk medications like tirzepatide.

Looking ahead, three key processes will shape obesity drug access in the coming year: the NICE appraisal of orforglipron, the Obesity Pathway Innovation Programme, and NICE's review of the funding variation. Access to obesity medications varies across the UK, with Scotland adopting different thresholds for eligibility. The current landscape of obesity drug access reveals a complex interplay of regulatory, funding, and delivery challenges that will continue to evolve in the coming years.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)